^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Mantle Cell Lymphoma |
| Regimen: | R-CVAD (cyclophosphamide + dexamethasone injection + pegylated liposomal doxorubicin + Rituxan (rituximab) + vincristine) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
01/20/2021
Excerpt:
Mantle Cell Lymphoma: INDUCTION THERAPY…Preferred Regimens…HyperCVAD (cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high-dose methotrexate and cytarabine) + rituximab
Secondary therapy:
cytarabine + methotrexate
